Meghana Keshavan

San Diego

Biotech Writer at STAT

Co-Writer at The Readout Newsletter

biotech nerd, biotech writer @statnews

Featured in: Favicon

statnews.com Favicon

businessinsider.com Favicon

foxnews.com Favicon

pbs.org

scientificamerican.com Favicon

flipboard.com Favicon

bostonglobe.com Favicon

wbur.org

theweek.com Favicon

medcitynews.com + 5 more

Articles

After groundbreaking CRISPR therapy, a homecoming

4 days ago | statnews.com | Meghana Keshavan

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! Baby KJ is back home! Also, we discuss the questionable efficacy of ctDNA blood tests, see what Vinay Prasad has to say at NORD, and more.
Pluvicto pushes earlier in prostate cancer play

5 days ago | statnews.com | Meghana Keshavan

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, STAT’s Matthew Herper chats with J&J’s R&D chief, we see the radiopharmaceutical Pluvicto being considered earlier for prostate cancer, and more.
Illumina's PromoterAI unlocks rare disease clues in noncoding genome

1 week ago | statnews.com | Meghana Keshavan

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Today, we discuss how one Brown contrarian and cancer researcher wants $50 billion for the NCI, we see a UniQure case study that shows its gene therapy helped reduce seizures, and more. As the big ASCO cancer conference kicks off today, Summit Therapeutics reported results via press release from a closely tracked study of its PD1-VEGF antibody ivonescimab.
Post-TIGIT flop, iTeos Therapeutics is shuttering

1 week ago | statnews.com | Meghana Keshavan

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we look at the implications of BARDA cutting a major vaccine contract with Moderna, hear why former FDA chief Scott Gottlieb thinks agency layoffs will impede progress on lowering drug prices, and more.
GlycoEra's global jobs underscore U.S. brain drain

1 week ago | statnews.com | Meghana Keshavan

Hello! Hope you had a nice extended weekend. Today, we talk about gene editing, particularly as it relates to pushing the field forward and how to maintain human dignity in the process. Also, a setback for Prothena, and a case for why biohacking doesn’t make sense. • Rocket Pharmaceuticals said a child with Danon disease, a severe, inherited heart condition, died after receiving treatment with the company’s gene therapy in a clinical trial.
Sanofi acquisition adds Alzheimer's drug to pipeline

2 weeks ago | statnews.com | Meghana Keshavan

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hey there. Today, we take a look at a biotech acquisition, ASCO’s new AI tool to help streamline cancer treatment guidelines, unpack the new restrictions on Covid-19 vaccines, and more.
Some scientists are getting their NIH research dollars back

2 weeks ago | statnews.com | Meghana Keshavan

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning! Today, we discuss how scientists are pushing back against NIH funding cuts, get to know Covid contrarian Tracy Beth Høeg, who is new at the FDA, and more. • Regeneron Pharma is buying 23andMe, the bankrupt genetic testing and database company, for $256 million.
Amgen loses $400 million antitrust battle to Regeneron

3 weeks ago | statnews.com | Meghana Keshavan

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today we start with some breaking newss: Novo Nordisk’s CEO is stepping down. We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron more than $400 million now, and more.
Insitro, Verastem treatment, chikungunya vaccine

1 month ago | statnews.com | Meghana Keshavan

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we talk about the FDA’s new artificial intelligence effort in the wake of mass layoffs, see AI darling Insitro cut staff, and more.
FDA will ask outside experts to review Capricor's therapy for Duchenne muscular dystrophy

1 month ago | statnews.com | Meghana Keshavan

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we explore how an ambitious nonprofit is taking control of a shelved gene therapy, as it seeks to create a new model for commercializing treatments no longer deemed lucrative by pharma. Also, we see global scientific worry over internal NIH emails that say international collaborations may be cut off.